Article Correctness Is Author's Responsibility: Arthritis Drug Presents Promise as Treatment for COVID-19 Pneumonia

The article below may contain offensive and/or incorrect content.

This shows someone holding a box of actemraUCSD has launched a Phase III clinical trial to assess whether tocilizumab (Actemra), a drug commonly prescribed for rheumatoid arthritis and other inflammatory disorders, has therapeutic value for those at risk of developing severe COVID-19 infection. The drug is a monoclonal antibody-based therapy that blocks receptors for interleukin-6, a cytokine that triggers inflammation as an early immune response to coronavirus. Blocking IL-6 could prevent the risk of the COVID-19 associated cytokine storm many with severe infection experience.